



## \$5.5 Million EBITDA Clinical Trial Company

**Listing Code:** **CACT1A**

American HealthCare Capital & PRIME exits, are pleased to introduce a clinical trial service business for sale that partners with physicians and pharmaceutical companies to accelerate clinical trials. At this time, 97% of Physicians and Patients do not have access to clinical trials. The company's goal is to assist both physicians and patients in the process. The business is a high-performing Investigator Site Network (ISN) consisting of over 6 million active patients and over 600 research physicians in a broad spectrum of therapeutic specialties. Sponsors will gain access to a network of physicians who work under one contract and budget. This business is ranked in the top 10% and was one of the top 50 research companies on the 2023 Inc 5000, its annual list of the fastest-growing private companies.

The business has had some very profitable years, and the future looks bright. In the year ending 2021, total revenue was \$2.967 Million with an EBITDA of \$987,000. In 2022, there was a large increase in sales, and the total revenue was \$6.972 million and an EBITDA of \$3 million. Halfway through 2024, the projected YE Revenue will be \$15 Million with an EBITDA of \$5.5 Million. This includes a study that is under contract and will begin in September of 2023. This contract will bring \$200,000 per month to the bottom line and runs through June 2024.

In the year ending 2021, total revenue was \$2.967 Million with an EBITDA of \$987K. In 2022 there was a large increase in sales and the total revenue was \$6.972 million and an EBITDA of \$3 million. Halfway through 2024 the projected YE Revenue will be \$15 Million with an EBITDA of \$5.5 Million. This includes a study that is under contract and will begin in September of 2023. This contract will bring \$200K a month to the bottom line and runs through June of 2024.

The company is also being considered for 29 additional studies that may start this year or that start next year. At this time, they are waiting to see if they will be awarded the studies. The net value of these 29 studies is \$2.8 million NET, and 15 of them have start dates in 2023. The future looks very encouraging!

To facilitate a successful and orderly transition, the current owner is willing to remain with the company during a transitional period. The owner is also open to being a consultant or part-time employee after the transition. The asking price for this opportunity is \$17 million.

To register your interest and be first to receive the Confidential Information Package, please email the listing advisor Dr. Allen Nazeri [Allen@pexits.com](mailto:Allen@pexits.com) or [Allen@Achteam.com](mailto:Allen@Achteam.com) or Paul Patrici [Paul@pexits.com](mailto:Paul@pexits.com)

[Sign NDA](#)